Migraine

As a CGRP receptor antagonist, zavegepant intervenes during the active phase of migraine, providing a targeted and prompt response to alleviate symptoms.

Be of value to patients and caregivers in forming a care plan for this challenging condition

Migraines are not a one-size-fits-all condition, and there is no one-size-fits-all solution.

Stress may have more of an effect on migraines than COVID-19 infection or vaccination.

Three classes of drugs could be 2 to 5 times more effective than ibuprofen for the treatment of migraine attacks, according to results of a study.

Zavegepant (Zavzpret; Pfizer) is the first and only only CGRP receptor antagonist as a nasal spray for the acute treatment of migraine in adults with and without aura approved by the FDA.

Pharmacists can make clinical recommendations tailored to patients’ individual needs.

Study investigators observed no significant differences in oxygen supplementation, hospitalization, or COVID-19 related death between initiators and non-initiators, though they cautioned more research was needed.

Patient retraces her treatment journey from diagnosis through treatment for glioblastoma.

Pharmacists play a key role in migraine management, therefore, awareness of menstrual migraine-specific prophylaxis is important.

Mobile apps can help consumers acquire medications, but few help with adherence beyond automatic refills or medication synchronization.

Studies consistently demonstrate the pivotal involvement of neuropeptide calcitonin gene related peptide release in migraine onset.

Galcanezumab-gnlm (Emgality; Eli Lilly and Company) did not demonstrate superiority to rimegepant orally disintegrating tablet (Nurtec ODT) on the percentage of individuals achieving a 50% or greater reduction in monthly migraine headache days.

Includes hair growth supplements and nicotine lozenges.

Access, diagnosis, and treatment for BIPOC patients suffering from migraines is yet another unflattering reflection of the lack of health equity in the United States.

Migraines can be a primary diagnosis or a symptom of an underlying medical or psychological condition.

Although an established standard of care for migraine prophylaxis exists, the current protocol is not without significant shortcomings.

Atogepant reduced mean monthly migraine days by more than 2 days compared to placebo in the ELEVATE trial.

Atogepant (Qulipta; AbbVie) is the first and only oral calcitonin gene-related peptide receptor antagonist to gain FDA approval for the prevention of episodic and chronic migraine.

The efficacy and tolerability of rizatriptan for acute migraine treatment has been well established.

Zavegepant is the only calcitonin gene-related peptide receptor antagonist nasal spray indicated for acute treatment of migraine in adults and can provide pain relief in 15 minutes.

Migraines are common yet misunderstood, therefore it is important that various treatment options be examined and offered to this patient population.

Zavegepant is the first calcitonin gene-related peptide receptor for migraines in development as an intranasal formulation studied in a phase 3 trial.

New research from Harvard Medical School could be a game changer for the management of headaches associated with anti-CGRP migraine therapy.

Students may be hesitant to discuss migraines, which can lead to absences, difficulties in personal life, financial burdens, and poor mental health.

Migraine could be considered a clinical marker of increased obstetric risk in pregnant women.

Patients with acute migraines should assess their condition before starting a treatment regimen.

There is a growing body of evidence that foods, substances, and additives in vitamins and supplements can be a trigger for migraine headaches.

Pharmacological options for those who experience migraines come in the form of abortive or preventative therapies.